{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:41:59Z","timestamp":1791549719395,"version":"4.3.4"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ejca.2025.115609","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T11:16:02Z","timestamp":1751973362000},"page":"115609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patients"],"prefix":"10.1016","volume":"226","author":[{"given":"Antoine","family":"Italiano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0818-4858","authenticated-orcid":false,"given":"Othilie","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2694-926X","authenticated-orcid":false,"given":"Jules","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5579-5264","authenticated-orcid":false,"given":"Tarek","family":"Assi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lama","family":"Dawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0838-2053","authenticated-orcid":false,"given":"Littisha","family":"Lawrance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4442-3876","authenticated-orcid":false,"given":"Alexandre","family":"Bone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghina","family":"Jardali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3869-3936","authenticated-orcid":false,"given":"Aurelie","family":"Choucair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Ammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Bayle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Henry","family":"Cournede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Borget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Lassau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejca.2025.115609_bib1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41416-023-02317-8","article-title":"Radiogenomics: a key component of precision cancer medicine","volume":"129","author":"Liu","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2025.115609_bib2","unstructured":"Avicenna.AI - Avicenna.AI Secures Two FDA Clearances For Stroke Assessment And Opportunistic PE [Internet]. [cited 2024 Sep 20]. Available from: \u3008https:\/\/avicenna.ai\/fda-clearances-aspects-and-ipe\/\u3009."},{"issue":"6","key":"10.1016\/j.ejca.2025.115609_bib3","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s13244-018-0657-7","article-title":"Radiomics and liquid biopsy in oncology: the holons of systems medicine","volume":"9","author":"Neri","year":"2018","journal-title":"Insights Imaging"},{"issue":"13","key":"10.1016\/j.ejca.2025.115609_bib4","doi-asserted-by":"crossref","first-page":"R150","DOI":"10.1088\/0031-9155\/61\/13\/R150","article-title":"Applications and limitations of radiomics","volume":"61","author":"Yip","year":"2016","journal-title":"Phys Med Biol"},{"issue":"6","key":"10.1016\/j.ejca.2025.115609_bib5","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1148\/rg.2021210037","article-title":"Radiomics in oncology: a practical guide","volume":"41","author":"Shur","year":"2021","journal-title":"RadioGraphics"},{"key":"10.1016\/j.ejca.2025.115609_bib6","first-page":"10","article-title":"Clinical, conventional CT and radiomic feature-based machine learning models for predicting alk rearrangement status in lung adenocarcinoma patients","volume":"10","author":"Song","year":"2020","journal-title":"Front Oncol [Internet]"},{"issue":"7","key":"10.1016\/j.ejca.2025.115609_bib7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.18632\/oncotarget.186","article-title":"EGFR-mutated lung cancer: a paradigm of molecular oncology","volume":"1","author":"Zhang","year":"2010","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.ejca.2025.115609_bib8","doi-asserted-by":"crossref","first-page":"12153","DOI":"10.3390\/ijms131012153","article-title":"Prognostic and predictive roles of KRAS mutation in colorectal cancer","volume":"13","author":"Arrington","year":"2012","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.ejca.2025.115609_bib9","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00259-019-04592-1","article-title":"Value of pre-therapy 18F-FDG PET\/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer","volume":"47","author":"Zhang","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.ejca.2025.115609_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-31806-7","article-title":"Predicting IDH genotype in gliomas using FET PET radiomics","volume":"8","author":"Lohmann","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ejca.2025.115609_bib11","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1186\/s12885-019-6341-6","article-title":"Characterizing MRI features of rectal cancers with different KRAS status","volume":"19","author":"Xu","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2025.115609_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0846537119899526","article-title":"Radiogenomic models using machine learning techniques to predict EGFR mutations in non-small cell lung cancer","volume":"72","author":"Nair","year":"2021","journal-title":"Can Assoc Radio J"},{"issue":"5","key":"10.1016\/j.ejca.2025.115609_bib13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00259-017-3885-z","article-title":"Value of 18F\u2013FDG PET\/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients","volume":"45","author":"Lv","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1016\/j.ejca.2025.115609_bib14","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115609_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.943253","article-title":"Circulating tumor DNA as a cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis","volume":"12","author":"S\u00e1nchez-Herrero","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.115609_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic \u2014 implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2025.115609_bib17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41568-019-0180-2","article-title":"Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells","volume":"19","author":"Keller","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2025.115609_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105643","article-title":"Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives","volume":"169","author":"Cucchiara","year":"2021","journal-title":"Pharm Res"},{"key":"10.1016\/j.ejca.2025.115609_bib19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fonc.2020.593831","article-title":"Integrating liquid biopsy and radiomics to monitor clonal heterogeneity of EGFR-positive non-small cell lung cancer","volume":"10","author":"Cucchiara","year":"2020","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115609_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12032-020-01353-1","article-title":"Will traditional biopsy be substituted by radiomics and liquid biopsy for breast cancer diagnosis and characterisation?","volume":"37","author":"Pesapane","year":"2020","journal-title":"Med Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2025.115609_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237802","article-title":"Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin","volume":"15","author":"Woodhouse","year":"2020","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ejca.2025.115609_bib22","unstructured":"FoundationOne CDx | Foundation Medicine [Internet]. [cited 2025 Jan 10]. Available from: \u3008https:\/\/www.foundationmedicine.com\/test\/foundationone-cdx\u3009."},{"key":"10.1016\/j.ejca.2025.115609_bib23","unstructured":"FoundationOne Liquid CDx | Foundation Medicine [Internet]. [cited 2025 Jan 10]. Available from: \u3008https:\/\/www.foundationmedicine.com\/test\/foundationone-liquid-cdx\u3009."},{"key":"10.1016\/j.ejca.2025.115609_bib24","first-page":"90","article-title":"An artificial intelligence model predicts the survival of solid tumour patients from imaging and clinical data","volume":"174","author":"Schutte","year":"2022","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"10.1016\/j.ejca.2025.115609_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.982790","article-title":"Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume","volume":"12","author":"Belkouchi","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2025.115609_bib26","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1007\/s00330-021-08520-6","article-title":"The application of radiomics in predicting gene mutations in cancer","volume":"32","author":"Qi","year":"2022","journal-title":"Eur Radio"},{"issue":"12","key":"10.1016\/j.ejca.2025.115609_bib27","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-020-1063-5","article-title":"Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies","volume":"26","author":"Nakamura","year":"2020","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ejca.2025.115609_bib28","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41416-018-0185-8","article-title":"A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features","volume":"119","author":"Saha","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2025.115609_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2019.108718","article-title":"Evaluating the HER-2 status of breast cancer using mammography radiomics features","volume":"121","author":"Zhou","year":"2019","journal-title":"Eur J Radio"},{"issue":"3","key":"10.1016\/j.ejca.2025.115609_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193871","article-title":"Radiogenomics analysis identifies correlations of digital mammography with clinical molecular signatures in breast cancer","volume":"13","author":"Tamez-Pena","year":"2018","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.ejca.2025.115609_bib31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic \u2014 implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2025.115609_bib32","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1093\/annonc\/mdx288","article-title":"Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions","volume":"28","author":"Mayo-de-Las-Casas","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115609_bib33","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","article-title":"Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Novello","year":"2016","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.ejca.2025.115609_bib34","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2025.115609_bib35","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1053\/j.gastro.2008.05.039","article-title":"Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients","volume":"135","author":"Diehl","year":"2008","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ejca.2025.115609_bib36","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1038\/s41598-018-24306-1","article-title":"Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients","volume":"8","author":"Guo","year":"2018","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.ejca.2025.115609_bib37","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2025.115609_bib38","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/annonc\/mdw261","article-title":"Outcome according to KRAS-, NRAS-and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group","volume":"27","author":"Modest","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.115609_bib39","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1007\/s00330-017-5146-8","article-title":"Can CT-based radiomics signature predict KRAS\/NRAS\/BRAF mutations in colorectal cancer?","volume":"28","author":"Yang","year":"2018","journal-title":"Eur Radio"},{"key":"10.1016\/j.ejca.2025.115609_bib40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejrad.2019.06.028","article-title":"CT texture analysis for the prediction of KRAS mutation status in colorectal cancer via a machine learning approach","volume":"118","author":"Taguchi","year":"2019","journal-title":"Eur J Radio"},{"key":"10.1016\/j.ejca.2025.115609_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2022.110640","article-title":"Current status and quality of radiomic studies for predicting KRAS mutations in colorectal cancer patients: a systematic review and meta\u2011analysis","volume":"158","author":"Jia","year":"2023","journal-title":"Eur J Radio"},{"issue":"5","key":"10.1016\/j.ejca.2025.115609_bib42","first-page":"2571","article-title":"Lack of association between KRAS mutations and 18F-FDG PET\/CT in Caucasian metastatic colorectal cancer patients","volume":"34","author":"Krikelis","year":"2014","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2025.115609_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3349\/ymj.2013.54.1.123","article-title":"Correlations of dynamic contrast-enhanced magnetic resonance imaging with morphologic, angiogenic, and molecular prognostic factors in rectal cancer","volume":"54","author":"Hong","year":"2013","journal-title":"Yonsei Med J"},{"issue":"9_ement","key":"10.1016\/j.ejca.2025.115609_bib44","article-title":"Clinical significance of ras oncogene activation in human lung cancer","volume":"52","author":"Rodenhuis","year":"1992","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2025.115609_bib45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00330-015-3814-0","article-title":"CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer","volume":"26","author":"Rizzo","year":"2016","journal-title":"Eur Radio"},{"issue":"6","key":"10.1016\/j.ejca.2025.115609_bib46","doi-asserted-by":"crossref","first-page":"590.e1","DOI":"10.1016\/j.crad.2018.01.009","article-title":"Comparison of CT radiogenomic and clinical characteristics between EGFR and KRAS mutations in lung adenocarcinomas","volume":"73","author":"Lv","year":"2018","journal-title":"Clin Radio"},{"issue":"3","key":"10.1016\/j.ejca.2025.115609_bib47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","article-title":"Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer","volume":"17","author":"Buscail","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7424","key":"10.1016\/j.ejca.2025.115609_bib48","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature11547","article-title":"Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes","volume":"491","author":"Biankin","year":"2012","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ejca.2025.115609_bib49","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMe2406495","article-title":"Osimertinib in Stage III EGFR-Mutated NSCLC \u2014 Game, Set, Match","volume":"391","author":"Leighl","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2025.115609_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-015-0714-8","article-title":"EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET\/CT scan","volume":"33","author":"Guan","year":"2015","journal-title":"Med Oncol"},{"key":"10.1016\/j.ejca.2025.115609_bib51","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejrad.2019.01.005","article-title":"Prediction of EGFR mutations by conventional CT-features in advanced pulmonary adenocarcinoma","volume":"112","author":"Chen","year":"2019","journal-title":"Eur J Radio"},{"issue":"2","key":"10.1016\/j.ejca.2025.115609_bib52","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.acra.2023.03.040","article-title":"Predicting EGFR mutation status in non\u2013small cell lung cancer using artificial intelligence: a systematic review and meta-analysis","volume":"31","author":"Nguyen","year":"2024","journal-title":"Acad Radio"},{"issue":"7","key":"10.1016\/j.ejca.2025.115609_bib53","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrc3760","article-title":"Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond","volume":"14","author":"Holderfield","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"10.1016\/j.ejca.2025.115609_bib54","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1002\/cncr.26086","article-title":"Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer","volume":"117","author":"Tran","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2025.115609_bib55","doi-asserted-by":"crossref","unstructured":"Shiota M., Akamatsu S., Tsukahara S., et al. Androgen receptor mutations for precision medicine in prostate cancer. 2022 [cited 2025 Jan 17]; doi: 10.1530\/ERC-22-0140.","DOI":"10.1530\/ERC-22-0140"},{"issue":"6_","key":"10.1016\/j.ejca.2025.115609_bib56","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1200\/JCO.2023.41.6_suppl.221","article-title":"Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history","volume":"41","author":"Bernard-Tessier","year":"2023","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2025.115609_bib57","doi-asserted-by":"crossref","first-page":"5631","DOI":"10.1158\/0008-5472.CAN-14-0476","article-title":"Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer","volume":"74","author":"Geng","year":"2014","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2025.115609_bib58","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/pros.24269","article-title":"Clinical and genomic features of SPOP-mutant prostate cancer","volume":"82","author":"Nakazawa","year":"2022","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.ejca.2025.115609_bib59","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.euo.2024.04.011","article-title":"Prognostic and predictive role of SPOP mutations in prostate cancer: a systematic review and meta-analysis","volume":"7","author":"Pedrani","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.115609_bib60","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.3390\/ijms23052571","article-title":"Non-invasive profiling of advanced prostate cancer via multi-parametric liquid biopsy and radiomic analysis","volume":"23","author":"Morrison","year":"2022","journal-title":"Int J Mol Sci"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925003910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925003910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:05:24Z","timestamp":1791360324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925003910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":60,"alternative-id":["S0959804925003910"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115609","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115609","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115609"}}